The purpose of our research was to evaluate whether ginsenoside Rb1 has neuroprotective effects
against lipopolysaccharide (LPS)-induced brain injury. ICR mice were
intraperitoneally (i.p.) injected with 20 or 40 mg/kg Rb1 or saline for 7
consecutive days. On the 7th day, 30 minutes after Rb1 or saline administration,
a single dose of LPS (LPS group, Rb1+LPS group) or saline (control group) was
injected i.p. into the mice. Results demonstrated that Rb1 treatment could
significantly improve the behavior performance of LPS mice in both the open field
test and the beam walking test. Rb1 can also markedly attenuate the neuronal
lesion in both hippocampus and somatosensory cortex in the brain of LPS mice. In
addition, Rb1 treatment also significantly inhibits the LPS-induced
neuroinflammation in the brain, indicated by reduced reactive microglia and
Neuroinflammation is a well-documented pathological event in neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis [1,2]. It is considered an important contributor to the pathogenesis and progression of neurodegeneration . Lipopolysaccharide (LPS), a gram-negative endotoxin, is well-known to mimic inflammatory conditions when administered to animals. The systemic inflammation by a single exposure to LPS transfers to the brain and primes a vicious circle of neuroinflammation with disruption of the blood–brain barrier (BBB), activation of glial cells, and production of a variety of proinflammatory cytokines in the brain that is detrimental to neurons [3-5]. Consequent cognitive impairment and depression-like behavior are also well documented [6-8]. Therefore, LPS-treated animals are widely used as neuroinflammation models of neuroprotection against neurodegeneration.
Glial cells, such as astrocytes, microglia, and oligodendrocytes, constitute a large fraction of the mammalian brain. Originally considered non-functional support for neurons, more and more research has highlighted the importance of glial cells in normal brain function [1,2]. Astrocytes perform several necessary functions for the formation and maintenance of the BBB and regulating brain water and ion homeostasis . One of the major functions of astrocytes within the CNS is to uptake excitatory glutamate, which is of central importance for maintaining glutamate–glutamine homeostasis to prevent neuron damage from glutamate-mediated excitotoxicity . For microglial cells, continuous and rapid surveillance is their unique feature in the brain. Microglia cells can recognize and engulf injured cells to prevent expanded neuron damage [2,11]. However, excessive activation of microglia cells is deleterious through self-propelling neuroinflammation, which impairs the optimal milieu for neuronal function, thereby contributing to neurodegeneration [2,11].
Ginseng has been used worldwide as traditional medicine for thousands of years. Several ingredients with multiple activities have been isolated from Ginseng, such as Rg1, Rb1, Rh2, Rg3, Rg5, and Re. Particularly, Rb1 has been proven more effective among all other ginsenosides in terms of anti-inflammation and repairing neuronal cell loss [12,13]. We previously found that Rb1 has significant effects in enhancing the expression of GLT-1 in astrocytes under oxygen-glucose deprivation and reoxygenation conditions (unpublished results). Given the importance of GLT-1 in regulating glial glutamate uptake and its consequent role in neuroinflammation , it is of value to investigate the effect of Rb1 on LPS-treated neuroinflammation and related neuronal lesions. We used LPS to induce neuroinflammation in mice and investigate the effects of Rb1. The results show that the administration of Rb1 in advance can significantly reduce the impairment of locomotor function and motor coordination caused by LPS. Rb1 significantly reduces neuroinflammation and neuronal cell damage both in the hippocampus and cerebral cortex. In addition, Rb1 can further enhance the LPS-induced GLT-1 expression and alleviate LPS-induced GS reduction in the brain.
Six-week-old male ICR mice (29–31 g, n = 80) were purchased from Vital River
Laboratory Animal Technology Co., Ltd. in Beijing, China (certificate number,
SCXK [Jing] 2016–0006). Mice in all groups were kept at 23
After 3 days of mice were fed, mice (n = 80) were randomly assigned to four groups (n = 20 per group), i.e., the control group, the LPS-treated group (LPS group), the 20 mg/kg Rb1 group (Rb1 20+LPS group) and the 40 mg/kg Rb1 group (Rb1 40+LPS group).
The experimental design. ICR mice were intraperitoneally (i.p.) injected with 20 or 40 mg/kg Rb1 or saline for 7 consecutive days. On the 7th day, 30 minutes after Rb1 or saline administration, a single dose of LPS (LPS group, Rb1+LPS group) or saline (control group) was injected i.p. into the mice. The locomotive activity was evaluated using the open-field test and the beam walking test at 20–24 h after the LPS injection. Mice were anesthetized with 7 mL/kg 1% pentobarbital sodium and transcardially perfused with ice-cold NS and 4% PFA 24 h after LPS injection for subsequent immunohistochemistry. Mice were anesthetized with 7 mL/kg 1% pentobarbital sodium and sacrificed 24 h after LPS injection for subsequent Western blot analysis and ELISA.
The locomotive activity was evaluated using the open-field test at 20 h after
the LPS injection (Fig. 1). Each mouse (n = 20 per group) was placed in the
center of an open field apparatus (W50
Mice (n = 20 per group) were trained for two days to walk from a start platform along a square beam (80 cm long, 3 cm wide) elevated 30 cm above the bench by supports to a goal box. Three trials to traverse the beam were performed for each mouse daily, and mice were excluded from the cohort if they could still not traverse the beam autonomously and smoothly after 2 days of training. On the third day, the mice were tested on the cylindrical beam (80 cm long, 8 mm diameter) after the open field test. The time to traverse each beam (up to 60 s) was recorded, and the performance on the beam was evaluated by the scoring system adapted from the method of Feeney et al. [16-18]. The higher the score, the better the mice performed. Mice that traversed the beam normally with no foot slip were given a score of “5”; those that traversed the beam successfully and foot slips occurred on less than half of the way were given a score of “4”; those that traversed the beam successfully and foot slips occurred on more than half of the way were given a score of “3”. Mice that fell from the beam were given a score of “2”,and those unable to place limbs on the beam surface were given a score of “1”. Such situations were allotted a maximum latency of 60 seconds. The walking beam apparatus was cleaned with 70% ethanol, and it was ensured that ethanol evaporated fully between trials.
Mice (n = 6 per group) were anesthetized with 7 mL/kg 1% pentobarbital sodium (Sigma, St. Louis, MO, USA) and transcardially perfused with ice-cold NS and 4% paraformaldehyde (PFA) (Servicebio, Wuhan, China) 24 h
after LPS injection. The brains were then placed in PFA and were preserved by
paraffin embedding. Sagittal sections at 5
Mice (n = 3 per group) were anesthetized with 7 mL/kg 1% pentobarbital sodium
and sacrificed 24 h after LPS injection. The brains were collected and
deep-frozen in liquid nitrogen followed by transfer to –80
Mice (n = 8–11 per group) were anesthetized with 7 mL/kg 1% pentobarbital
sodium (Sigma, St. Louis, MO, USA) and sacrificed 24 h after LPS injection. The brains were collected and
deep-frozen in liquid nitrogen and stored at –80
For statistical analysis, all data are presented using GraphPad Prism 6.01 (GraphPad Software Inc., San
Diego, CA, USA) for statistical analysis. One-way analysis of variance (ANOVA)
followed by an LSD test or Tamhane’s T2 test was performed. And if the data were not
normal, Kruskal-Wallis of the non-parametric test was performed; p values
It has been reported that systemic inflammation induced by LPS can lead to behavioral disorders, including sensorimotor deficits and cognitive impairment. Thus, we firstly investigated the effects of Rb1 on the LPS-induced behavior changes by using the open-field test, which is regarded as a comprehensive quantitative assessment of voluntary activities and exploration behaviors . Compared to control mice, reduced voluntary locomotor activity as indicated by slow walking and decreased activity was observed in mice treated with LPS, as shown in Fig. 2. Rb1 treatment improved the abnormal behavior caused by LPS, manifested as prolonged movement distance and increased movement speed (Fig. 2B–F), although the dose–effect relationship is not obvious. The results conclusively indicate that Rb1 relieves the behavior changes caused by LPS and improves locomotive activity.
Rb1 improved the locomotive activities in LPS-treated mice. The
locomotive activity was monitored using the open-field test between 20 h and
24 h after the LPS injection. The track maps of different groups (A), and
quantitative analysis of total distance, crossing lines, moving and stand still
duration, average velocity during 5 min (B–F) are listed. Data are represented
It has been reported that the beam walking assay is a more sensitive tool for monitoring sensorimotor function in rodents than locomotor studies . To further examine the effect of Rb1 on motor impairment in LPS mice, we investigated motor coordination using the beam walking test with some modification [16,18,20]. The crossing performance is scored, and the time crossing the beam is recorded. A higher score indicates a better crossing performance. After two days of training, most mice could not cross the beam within a few seconds. Mice with poor training performance were excluded from the cohort. On the third day, the beam walking performance was tested. There were no foot slips or falls observed in control mice (Fig. 3A). However, as shown in Fig. 3, LPS mice were becoming slow when crossing the beam, and a significant number of foot slips or falls were observed in LPS-treated mice (Fig. 3B,D). Some of the LPS-treated mice were could not to cross the beam, and some could not even place their limbs on the beam (Fig. 3C). Compared to LPS mice, the mice in the 20 mg/kg and 40 mg/kg groups had a much better performance crossing the beam, with fewer foot slips (Fig. 3E,F). No falls were observed in both the Rb1 20 mg/kg and 40 mg/kg groups. The results suggest that Rb1 improved the motor coordination of LPS treated mice.
Rb1 improved LPS-induced motor coordination deficits. The beam
walking assay was used to determine motor coordination between 20 h and 24 h
after LPS injection. The images illustrate the performance for the beam walking
test, including traversing the beam normally (A), or hindfoot slips (B) with
difficulties to place the hindfoot on the beam (C) or falls from the beam (D).
The performance of the mice crossing the beam was as evaluated with scoring (E),
and a higher score represents a better performance on the beam. The time crossing
the beam to reach the goal box was also recorded (F). Data are represented as
The primary somatosensory cortex and hippocampus are important sections of the brain responsible for regulating voluntary and involuntary movement. They also facilitate the control of motor coordination . To explore the underlying reason for the locomotor changes, we investigated the neuronal injury in the cortex and hippocampus by immunostaining neurons with NeuN, a neuronal nuclear marker , in S1Tr, S1BF, and S2 areas of the somatosensory cortex and CA1 in the hippocampus (Fig. 4A). As shown in Fig. 4, LPS treatment mildly reduced the NeuN in all the above regions compared to the control mice (Fig. 4B–D). Rb1 20 mg/kg and 40 mg/kg treatments significantly attenuated LPS-induced neuronal loss (Fig. 4B–D). However, Rb1 40 mg/kg did not show a greater effect than 20 mg/kg. The above immunostaining results indicate that Rb1 protects neurons from LPS-induced damage.
Rb1 attenuated neuron loss in the brain following LPS
treatment. Immunostaining was performed 24 h after LPS i.p. injection. The NeuN
positive cells in CA1, S1Tr, S1BF, and S2 were monitored (Red boxes) (A). The
immunostaining of NeuN-labeled cells (Green) was presented in CA1, S1Tr, S1BF,
and S2 areas (B). NeuN+DAPI or NeuN positive cells in the
hippocampus (C) and somatosensory motor cortex (D) were counted. Data are
represented as mean
Excessively activated microglia are suggested to be directly or indirectly
involved in neuroinflammation and consequent neuronal injury [11,14]. To
understand the neuroprotective effects of Rb1 following LPS insult, we
investigated microglial activation as depicted by IBa-1-positive cells in CA1,
S1Tr, S1BF and S2 areas. The production of IL-1
Rb1 treatment suppressed the LPS-induced
microglial activation and inhibited the production of IL-1
Astrocytes and microglia are two interrelated and interacting cells involved in maintaining brain function. Systemic exposure to endotoxin has been shown to activate microglia and astrocytes . LPS-induced astrocytes activated to A1 subtypes are suggested to be harmful to neurons in the brain . Although the mechanisms by which A1 subtypes act as “bad players” remain unknown, it is helpful to monitor the GLT-1 and GS after LPS insult because more than 90% of the glutamate released into the synaptic cleft is not taken by GLT-1 on the astrocyte membrane, and most of the glutamate entering into astrocytes is converted into glutamine by GS to avoid excitotoxicity . As shown in Fig. 6, systemically LPS administration led to reactive astrogliosis in hippocampus CA1 characterized by hypertrophy and an increasing number of GFAP-labeled cells, along with considerable expression of GLT-1 transporter (Fig. 6A,B,E). However, the expression of GS was reduced after LPS treatment (Fig. 6C,D,F). Rb1 20 mg/kg and 40 mg/kg treatments further enhanced the production GLT-1 in astrocytes after LPS insult and significantly attenuated the GS reduction induced by LPS, which was confirmed by both immunostaining and Western Blot analysis. The results reveal that Rb1 can further increase the expression of GLT-1 and attenuate the GS reduction induced by LPS insult.
Rb1 upregulated the
expression of GLT-1 and GS in LPS mice. Western Blot and immunostaining were
performed 24 h after LPS i.p. injection. Expressions of GLT-1 and GS in the brain
were evaluated by Western blot analysis (A,C). The quantification of GLT-1
and GS were normalized by the expression of
We demonstrated that Rb1 administered in advance has neuroprotective effects in LPS-injected mice. Rb1 can improve the locomotor function and motor coordination of LPS mice. Rb1 can prevent neuronal cell loss and inhibit neuroinflammation in the hippocampus and somatosensory cortex caused by LPS injection. In addition, Rb1 can further enhance the LPS-induced GLT-1 expression and alleviate LPS-induced GS reduction in the brain. Taken together, Rb1 has neuroprotective effects against LPS-induced neuroinflammatory lesions in the brain of mice. Rb1 regulation of the expression of GLT-1 and GS may be involved in its effects.
We presumed that the Rb1 improvement in LPS-induced locomotor and motor coordination deficits reduced voluntary activities, decreased locomotor speed, and impaired motor coordination) due to its neuronal protection on the somatosensory cortex and hippocampus. As illustrated by NeuN immunostaining, 24 h following i.p. injection of LPS at 3 mg/kg, there is evidence of neuronal loss in S1Tr, S1BF, and S2 of the somatosensory cortex, as well as in CA1 of the hippocampus. Rb1 administered on 7 consecutive days in advance significantly alleviated the LPS induced neuronal loss and improved the motor functions in LPS mice. These results not only confirm our presumption as mentioned above, but they also shed light on the findings that Rb1 improves learning and memory, as well as the sensorimotor system, in several other studies [27-29].
In the brain, inflammatory response, termed neuroinflammation, is a fundamental
response generated to protect the neuronal system. Microglia is the key player in
neuroinflammation in the brain. Microglia engage in environmental surveillance in the “rest” stage by constantly sampling areas around them to maintain homeostasis [11,30]. Upon activation, microglia can release several
cytokines and process the intruders or “dying” cells to prevent further
injury. However, uncontrolled or prolonged microglial activation is potentially
harmful and can result in other neuronal lesions. We found that
LPS induced a profound microglial activation with significantly increased
Astrocytes play an essential role in maintaining glutamate homeostasis depending on excitatory amino acid transporters (EAATs) and GS. GLT-1 is preferentially expressed in astrocytes and transfers glutamate from the synaptic cleft to astrocytic intracellular space to avoid glutamate excitotoxicity . Once taken up by astrocytes, in addition to re-entry into the extracellular space or TCA cycle, most of the glutamate coverts to glutamine by GS , which serves as the substrate for the synthesis of glutamate and GABA in corresponding neuronal cells. Recent findings suggest that sustained microglial activation leads to failure in astrocytic normal resolution mechanisms of excitatory glutamate [14,32,33]. Present findings show that LPS insult resulted in an increased GLT-1expression and decreased GS expression, indicating a compromised function of glutamate cycling, which is believed to participate in gliotoxic effects of LPS due to overloading of glutamate inside the astrocytes [32,34,35]. Promisingly, for the first time, we found that Rb1 further enhanced the GLT-1 expression and significantly increased the GS expression in the brain of LPS mice. This result explains from another perspective why Rb1 has neuroprotective effects against LPS insult.
The ginsenosides, also known as steroid-like saponins, are the major active pharmacological components of ginseng. More than 100 ginsenosides have been identified . Several recent studies have presented evidence showing that ginsenosides could be used to prevent and treat various inflammatory diseases . It was reported that ginsenoside Rb1 is regarded as the main compound responsible for the neuroprotective effects of ginsenosides . In addition, our previous findings suggest that Rb1 plays a protective role in astrocytic dysfunction in light of enhanced expression of GLT-1and GS following oxygen and glucose deprivation (OGD/R). We demonstrated that Rb1 has neuroprotective effects against LPS insult and can regulate the glutamate cycling system, indicated by GLT-1 and GS. Given the importance of glutamate in brain function, it is reasonable to assume that regulating GLT-1/GS may be the common mechanism for Rb1 protecting neuron lesions in various insults. This is further supported because, in addition to LPS insult and OGD/R insult, we also found that Rb1 can significantly alleviate pentylenetetrazol-induced seizure symptoms in mice and improve GLT-1/GS expression in the brain (Unpublished results).
In conclusion, our findings indicate that Rb1 has neuroprotective effects against LPS insults in mice, closely correlated with the Rb1 improvement of somatosensory motor impairment. Rb1 regulation of perturbation glial cells, including microglia and astrocyte, may involve its neuroprotection. Until now, scientific evidence has been lacking as to why ginsenosides (including Rb1) have been reported to have neuronal protective effects against several distinct insults. The present work may shed light on understanding the underlying mechanisms. This further understanding of the mechanism by which Rb1 regulates the GLT-1/GS system further supports its potential for treating neurodegenerative diseases.
BBB, blood-brain barrier; CNS, central nervous system; EAATs, excitatory amino
acid transporters; Glu, glutamate; Gln, glutamine; GLT-1, glutamate
transporter-1; GS, glutamine synthase; GFAP, glial fibrillary acidic protein;
IBa-1, ionized calcium-binding adapter molecule-1; IL-1
HZ and MT designed the experiments, HZ, XC, XW, and YL performed and analyzed the data. MT contributed reagents and materials. HZ wrote the paper, and MT, CDS edited the paper. All authors read and approved the final manuscript.
Animals were raised and handled at the Laboratory Animal Center of the Beijing University of Chinese Medicine, Beijing. All animal experiments were carried out in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals, and the Institutional Animal Care and Use Committee of Beijing University of Chinese Medicine approved the protocol (BUCM-4-2020100803-4136, 8 October 2020). The datasets were obtained with the informed consent of all participants.
We thank four anonymous reviewers for their excellent criticism of the article.
This research was supported by the grant “International Cooperation Project of Prevention and Treatment of Major Diseases with Chinese Medicine (0610-2040N F020928)”,“High-end Experts Support Program from the Ministry of Science and Technology (DL 20200001008)”,“Basic Research Funds from the Ministry of Education (No. 1000061223731)”.
The authors declare no conflict of interest.